Regulation of next generation sequencing

Journal of Law, Medicine and Ethics

Volumn 42, Issue s1, 2014, Pages 9-21

  Javitt, Gail H ^a   Carner, Katherine Strong ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Allen Boone Humphries Robinson LLP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORY SERVICE; DNA SEQUENCE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; LEGISLATION AND JURISPRUDENCE; UNITED STATES;

CLINICAL LABORATORY SERVICES; GENOME, HUMAN; GOVERNMENT REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; SEQUENCE ANALYSIS, DNA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907865650     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/jlme.12159     Document Type: Article

References (24)

1. E. S. Lander, L. M. Linton, and B. Birren et al., "Initial Sequencing and Analysis of the Human Genome, " Nature 409, no. 6822 (2001): 860-921; Celera Genomics' results from its parallel project were published at the same time:
2. J. C. Venter, M. D. Adams, and E. W. Myers et al., "The Sequence of the Human Genome, " Science 291, no. 5507 (2001): 1304-1351.
3. J. M. Conley, A. K. Doerr, and D. B. Vorhaus, "Enabling Responsible Public Genomics, " Health Matrix 20, no. 2 (2010): 325-385, at 330-331.
4. See J. Shendure and E. Lieberman Aiden, "The Expanding Scope of DNA Sequencing, " Nature Biotechnology 30, no. 11 (2012): 1084-1094 (noting that, between 2005 and 2012, the cost of DNA sequencing has dropped from $1, 000 per megabase to ten cents per megabase)
5. E. C. Hayden, "Technology: The $1000 genome, " Nature 507, no. 7492 (2014): 294-295
6. L. G. Biesecker, "Opportunities and Challenges for the Integration of Massively Parallel Genomic Sequencing into Clinical Practice: Lessons from the ClinSeq Project, " Genetics in Medicine 14, no. 4 (2012): 393-398.
7. M. Heger, "FDA Official Discusses Issues with Regulating NGS Dx Tests, " Genome Web (2012), available at (last visited July 8, 2014).
8. F. Sanger, S. Nicklen, and A. R. Coulson, "DNA Sequencing with Chain-Terminating Inhibitors, " Proceedings of the National Academy of Sciences of the United States of America 74, no. 12 (1977): 5463-5467. In the same year, Allan Maxam and Walter Gilbert published an alternative approach in which terminally labeled DNA fragments were subject to base-specific chemical cleavage and the reaction products were separated by gel electrophoresis. See A. Maxam and W. Gilbert, "A New Method for Sequencing DNA, " Proceedings of the National Academy of Sciences of the United States of America 74, no. 2 (1977): 560-564. The Sanger method, which was subsequently refined and commercialized, became the dominant method in both research and clinical diagnostics
9. K. Voelkerding, S. Dames, and J. Durtschi, "Next Generation Sequencing: From Basic Research to Diagnostics, " Clinical Chemistry 55, no. 4 (2009): 641-658.
10. K. Voelkerding, S. Dames, and J. Durtschi, "Next Generation Sequencing: From Basic Research to Diagnostics," Clinical Chemistry 55, no. 4 (2009): 641-658.
11. C. Wright, H. Burton, and A. Hall et al., "Next Steps in the Sequence: The Implications of Whole Genome Sequencing for Health in the UK, " PHG Foundation (2011), available at (last visited July 8, 2014).
12. J. S. Ware, A. M. Robers, and S. A. Cook, "Next Generation Sequencing for Clinical Diagnostics and Personalised Medicine: Implications for the Next Generation Cardiologist, " Heart 98, no. 4 (2012): 276-281; Voelkerding et al., supra note 8.
13. M. L. Metzker, "Sequencing Technologies - The Next Generation, " Nature Reviews Genetics 11, no. 1 (2010): 31-46.
14. J. Bras, R. Guerreiro, and J. Hardy, "Use of Next-Generation Sequencing and Other Whole-Genome Strategies to Dissect Neurological Disease, " Nature Reviews: Neuroscience 13, no. 7 (2012): 453-464.
15. Q. C. Ma, C. A. Ennis, and S. Aparicio, "Opening Pandora's Box - The New Biology of Driver Mutations and Clonal Evolution in Cancer as Revealed by Next Generation Sequencing, " Current Opinion in Genetics & Development 22, no. 1 (2012): 3-9.
16. S. E. Calvo, A. G. Compton, and S. G. Hershman et al., "Molecular Diagnosis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing, " Science Translational Medicine 4, no. 118 (2012): 118ra10.
17. R. W. Chiu, R. Akolekar, and Y. W. Zheng et al., "Non-Invasive Prenatal Assessment of Trisomy 21 by Multiplexed Maternal Plasma DNA Sequencing: Large Scale Validity Study, " British Medical Journal (Clinical Research ed.) 342 (2011): c7401.
18. L. G. Biesecker, W. Burke, and I. Kohane et al., "Next-Generation Sequencing in the Clinic: Are We Ready?" Nature Reviews. Genetics 13, no. 11 (2012): 818-824.
19. B. A. Goldberger, "The Evolution of Substantial Equivalence in FDA's Premarket Review of Medical Devices, " Food and Drug Law Journal 56, no. 3 (2001): 317-318.
20. G. H. Javitt and K. Strong Carner, "Must FDA Engage in Rule-making to Regulate Laboratory-Developed Tests?" The Food and Drug Law Institute's Food and Drug Policy Forum 1, no. 17 (September 14, 2011).
21. M. Ashford, "At Dx Conference, FDA's Gutierrez Sheds Further Light on Plans for Risk-Based LDT Regulation, " GenomeWeb Pharmacogenomics Reporter (September 7, 2011), available at (last visited July 8, 2014) ("Gutierrez told attendees that risk classification for LDTs will mirror largely what the FDA already does for in vitro diagnostics. 'Anything already defined class III [as an IVD] will stay as class III [if an LDT makes the same claim], ' he said.")
22. A. S. Gargis, L. Kalman, and M. W. Berry et al., "Assuring the Quality of Next-Generation Sequencing in Clinical Laboratory Practice, " Nature Biotechnology 30, no. 11 (2012): 1033-1036.
23. H. L. Rehm, S. J. Bale, P. Bayrak-Toydemir et al., "ACMG Practice Guidelines: ACMG Clinical Laboratory Standards for Next-Generation Sequencing, " Genetics in Medicine 15, no. 9 (2013): 733-747.
24. A. Nekrutenko and J. Taylor, "Next-Generation Sequencing Data Interpretation: Enhancing Reproducibility and Accessibility, " Nature Reviews Genetics 13, no. 9 (2012): 667-672.